Cells affected by Hutchinson-Gilford Progeria Syndrome ( HGPS ), a disease associated with premature aging, can be made healthy again, according to findings by scientists at the National Cancer Institute ( NCI ), part of the National Institutes of Health ( NIH ).

Using specially modified segments of DNA, NCI researchers Paola Scaffidi and Tom Misteli reversed the abnormalities seen in HGPS cells by correcting defects associated with the key protein, lamin A. By demonstrating that HGPS cellular characteristics are reversible.

This study has been published in Nature Medicine.

HGPS is a rare inherited disease affecting about one in eight million children. While appearing normal at birth, infants with HGPS age rapidly after their first 18 months, and physical symptoms include stunted growth, loss of hair and body fat, joint stiffness, osteoporosis, and heart problems.
The condition is fatal, with heart disease being the leading killer, and affected children usually die before they reach their late teens.

Less than two years ago, NIH-led researchers discovered that the genetic basis for HGPS is a single mutation in the gene encoding lamin A.
Lamin A is a critical structural protein that acts as the scaffolding which holds a cell’s nucleus together.
Lamin A is defective in HGPS cells because the mutation creates an aberrant splice site in the lamin A gene; the aberrant splicing, or joining the separate parts of the gene together, results in synthesis of a truncated lamin protein.
Without lamin A holding them together, the nuclei of progeria cells become wrinkled and misshapen.
In addition, numerous other nuclear proteins show reduced expression.

“ Our team at the Center for Cancer Research in Bethesda set out to ask whether these cellular changes associated with progeria are permanent or reversible, ” said Scaffidi.

First, the investigators added DNA encoding normal lamin A into cells taken from patients affected with progeria, but observed that increased synthesis of normal lamin A did not correct any of the progeria-associated defects.
In addition, they found that introduction of the mutant protein into healthy human cells was sufficient to produce the disease characteristics.
“ These results made it clear that in order to achieve a potential therapeutic effect, we needed to completely eliminate the mutant protein, ” said Scaffidi.

The NCI researchers designed a chemically stable DNA oligonucleotide, a short DNA sequence that the cell wouldn’t be able to degrade, that would bind to the mutant splice site and prevent the splicing machinery from cutting in the wrong place.
The researchers inserted their oligonucleotides into the progeria cells and observed that after four days almost all the mutant lamin A transcripts had been eliminated and replaced with the properly spliced counterpart.
The oligonucleotide was highly specific to the mutated region and did not cover-up other splicing locations.

One week after correcting the splicing defect, the mutant lamin A protein had been eliminated and more than 90 percent of progeria cells were restored to normal; visually, the nuclei lost their wrinkles and lobes and returned to a natural ellipsoid shape, and the expression of other nuclear proteins was also restored to normal levels.

“ It’s amazing that we could take a cell that looked about ready to die, and a few days later it was healthy and ready to divide again, ” said Misteli.

Misteli noted that these results demonstrate a proof-of-principle that the cellular effects of progeria can be reversed, meaning his laboratory’s method could be used some day in the future as a therapeutic strategy.
The fact that a progeria reversal can be achieved in multiple cell types, and that the cells can return to normal, independent of cell division, bolsters this possibility.
“ Some tissues in our body do not divide, ” Misteli pointed out. “ So demonstrating that we can rescue the normal phenotype without cell division means this procedure could be effective in all tissues. ” Misteli and his group will also look more closely at healthy cells to determine how similar progeria is to the normal aging process.

Source: NIH, 2005


XagenaMedicine2005